Quick Comparison
| PEA (Palmitoylethanolamide) | Reishi | |
|---|---|---|
| Half-Life | 1-2 hours (rapidly metabolized). Micronized forms have improved bioavailability | Bioactive compounds accumulate with daily use |
| Typical Dosage | Standard: 300-1200 mg daily in 2-3 divided doses. Start at 600 mg daily. Micronized or ultra-micronized (um-PEA) forms have much better absorption. For chronic pain: 600 mg twice daily. For neuroinflammation: 400-600 mg twice daily. Effects build over 2-4 weeks. | Standard: 1000-3000 mg daily of extract. Dual-extract (water + alcohol extraction) preferred to capture both polysaccharides and triterpenes. Take in the evening due to calming effects. Spore oil: 500-1000 mg daily. Effects build over 2-4 weeks. |
| Administration | Oral (capsules, powder). Micronized (m-PEA) or ultra-micronized (um-PEA) forms preferred for bioavailability. | Oral (capsules, powder, tincture, tea). Dual-extract preferred. Bitter taste in powder/tea form. |
| Research Papers | 10 papers | 8 papers |
| Categories |
Mechanism of Action
PEA (Palmitoylethanolamide)
PEA activates PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear receptor that heterodimerizes with RXR and downregulates pro-inflammatory gene expression (NF-kB target genes, COX-2, iNOS, TNF-alpha). It has an 'entourage effect' on the endocannabinoid system — it inhibits the degradation of anandamide by fatty acid amide hydrolase (FAAH) through allosteric modulation or substrate competition, and upregulates CB2 receptor expression on immune cells. This provides anti-inflammatory and analgesic effects without directly activating CB1/CB2. PEA also activates GPR55 and GPR119. It inhibits mast cell degranulation (reducing histamine, tryptase, and cytokine release) and reduces microglial activation in the brain (inhibiting Iba1 expression and pro-inflammatory cytokine production). PEA may also modulate TRPV1.
Reishi
Reishi's triterpenes (ganoderic acids A, C, D, H; ganoderenic acids) modulate the HPA axis by reducing CRH and ACTH release, lowering cortisol via glucocorticoid receptor feedback. Ganoderic acids have direct sedative effects through GABA-A receptor modulation (possibly allosteric at the benzodiazepine site) and 5-HT2A/2C serotonergic modulation. Beta-(1,3)-(1,6)-glucan polysaccharides bind Dectin-1 and complement receptor 3 (CR3) on macrophages, natural killer cells, and dendritic cells, activating NF-kB and MAPK signaling for immune modulation. Reishi inhibits histamine release from mast cells via Fc epsilon RI downregulation and stabilizes mast cell membranes (anti-allergic effect). Antioxidant properties involve upregulation of superoxide dismutase (SOD1/SOD2), catalase, and glutathione peroxidase. Ganoderic acids may also inhibit 5-alpha-reductase and ACE.
Risks & Safety
PEA (Palmitoylethanolamide)
Common
Very well-tolerated — rare side effects. Mild GI discomfort.
Serious
None documented. Over 30 clinical trials confirm excellent safety profile.
Rare
Skin rash.
Reishi
Common
Digestive discomfort, dry mouth, dizziness.
Serious
Rare hepatotoxicity reported — avoid with liver disease. May interact with blood thinners and immunosuppressants.
Rare
Allergic reaction, nosebleeds.
Full Profiles
PEA (Palmitoylethanolamide) →
An endogenous fatty acid amide produced naturally in the body in response to pain and inflammation. PEA activates PPAR-alpha receptors and indirectly enhances endocannabinoid signaling without binding to cannabinoid receptors. It has strong evidence for neuropathic pain, neuroinflammation, and neuroprotection. Unlike anti-inflammatory drugs, it resolves inflammation rather than merely suppressing it.
Reishi →
Known as the 'mushroom of immortality' in Chinese medicine, Reishi (Ganoderma lucidum) is an adaptogenic mushroom primarily used for stress reduction, immune support, and sleep improvement. Unlike the stimulating effects of Cordyceps or Lion's Mane, Reishi is calming and is best taken in the evening. Its triterpene compounds modulate the HPA axis and support GABAergic relaxation.